Ashland Inc.

Ashland Inc. (ASH) Market Cap

Ashland Inc. has a market capitalization of $2.57B.

Price: $56.20

▼ -0.87 (-1.52%)

Market Cap: 2.57B

NYSE ¡ time unavailable

CEO: Guillermo Novo

Sector: Basic Materials

Industry: Chemicals - Specialty

IPO Date: 1980-03-17

Website: https://www.ashland.com

Ashland Inc. (ASH) - Company Information

Market Cap: 2.57B|Sector: Basic Materials

Company Profile

Ashland Inc. provides additives and specialty ingredients worldwide. It operates through Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions. The Personal Care & Household segment provides a range of nature-based, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. The Intermediates and Solvents segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. The company was formerly known as Ashland Global Holdings Inc. Ashland Inc. was founded in 1924 and is based in Wilmington, Delaware.

Analyst Sentiment

76%
Strong Buy

From 12 Active Polls

1Y Forecast: $67.38

▲ +19.9% Potential Upside

Consensus Target Metrics

Low Bound

$58

Median

$70

High Bound

$75

Average

$67

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$67.38
▲ +19.89% Upside
Low Target
$58.00
3% Risk
Median Target
$70.00
25% Mid
High Target
$75.00
33% Max
Consensus
Buy
16 / 24 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)2,5732,5462,6992,2042,3132,7093,3594,0884,604
Enterprise Value ($M)3,7083,6813,9673,4823,5914,0284,5565,2565,651
Price to Earnings Ratio (P/E)-3.6439.79-56.2317.22-0.7821.85-5.0963.87191.81
Price/Earnings-to-Growth Ratio (PEG)—1.60—5.31—1.20———
Price to Sales Ratio (P/S)1.425.286.994.615.005.668.297.838.46
Price to Book Ratio (P/B)1.381.361.441.171.221.061.301.431.55
Price to Free Cash Flow Ratio (P/FCF)7.70106.0924.3125.6320.47-135.46-53.31140.9552.91
Enterprise Value to Sales (EV/Sales)—7.6410.287.287.768.4111.2510.0710.39
Enterprise Value to EBITDA (EV/EBITDA)10.0846.0276.2826.7833.8835.3460.7456.511883.50
Debt to Equity Ratio3.080.790.840.790.790.580.550.510.49

⚡ ASH Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$56.20
Intrinsic Value$6.85
Market Alignment
Overvalued by 87.8%relative to calculated intrinsic value
9.00%
Exp: -3%-3%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.10B
Perpetuity TV Value$1.85B
Discounted TV (PV)$0.78B
TV Weighting %55.1%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ASHLAND INC (ASH) — Investment Overview

🧩 Business Model Overview

Ashland is a specialty chemicals provider that sells performance-focused materials and solutions into industrial and consumer-facing end markets. The business model is built around tailoring formulations to customer requirements (performance, processability, regulatory compliance, and end-use characteristics) and supplying those products through a global manufacturing and distribution footprint.

Value creation typically occurs across three steps: (1) application development and technical service to qualify products in customer processes, (2) manufacturing and blending to deliver consistent quality at scale, and (3) supply reliability supported by owned/contracted production capacity and logistics. Customer stickiness is reinforced because many downstream applications require testing, qualification, and process adjustments, turning “like-for-like” substitution into a high-friction decision.

💰 Revenue Streams & Monetisation Model

Revenue is predominantly tied to customer purchases of formulated specialty products and additive systems, with monetisation driven by both pricing and volume in cyclical industrial conditions. While some product categories can behave more transactionally, overall monetisation tends to include a recurring element created by approved supply relationships—particularly where customers run long-lived product specs or consume continuous inputs for compounding, coatings, adhesives, or asphalt-related applications.

Margin drivers are usually anchored in:

  • Differentiated formulations that support pricing power versus commodity-like chemicals.
  • Operational leverage from plant utilization and supply chain execution in a business with fixed overhead.
  • Mix (higher value-added product families vs. more commoditized offerings).
  • Technical service intensity that reduces customer switching and supports higher gross margins.

🧠 Competitive Advantages & Market Positioning

Ashland’s core moat is best characterized as high switching costs plus intangible, application-based capabilities. Competitors can produce many chemical substances, but reproducing customer-qualified performance in specific processes—at the same quality, regulatory profile, and cost-to-serve—typically requires time, testing, and shared technical know-how. This creates a barrier to substitution once a product becomes embedded in a customer’s specification.

This positioning contrasts with more broadly diversified commodity chemicals players that compete primarily on scale and feedstock economics.

Competitive benchmarking (primary peers):

  • Dow: broader chemical platform and scale; competes across a wider set of base and specialty products, often emphasizing scale and portfolio breadth rather than deep niche application qualification per customer process.
  • Evonik: strong in specialty additives and performance materials; competes in overlapping segments where technical differentiation drives qualification cycles.
  • BASF: integrated chemicals supplier with extensive specialty offerings; competes through portfolio depth, global manufacturing footprint, and customer-facing R&D.

Relative to these rivals, Ashland’s advantage tends to concentrate on focused specialties where qualification, formulation know-how, and reliable supply create stickiness—rather than competing as a pure low-cost volume producer.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, the most durable growth drivers for a specialty chemicals model like Ashland’s typically include:

  • End-market complexity and performance demand: customers increasingly require engineered material properties (adhesion, durability, compatibility, temperature performance, and process efficiency) that favor application-qualified suppliers.
  • Product substitution from less efficient chemistries: regulations and customer specifications can favor higher-performing, lower-emissions, or more efficient formulations—supporting share gains within technical niches.
  • Capacity and supply reliability in qualified categories: delivering consistent quality and uninterrupted supply strengthens approved-supplier status, supporting incremental volume from existing customers and improving conversion of new projects.
  • Technical services as a TAM expansion lever: R&D and co-development can expand addressable demand by moving customers from “existing formulations” to “process-improved formulations” rather than competing only on price.

TAM expansion is less about broad commodity growth and more about expanding the penetration of engineered specialties within industrial systems and product formulations, where the economic buyer is selecting performance outcomes and supply reliability.

⚠ Risk Factors to Monitor

  • End-market cyclicality: industrial and consumer-adjacent demand can shift quickly, impacting volume and operating leverage.
  • Feedstock and energy volatility: input cost movements can pressure margins without immediate pass-through via pricing.
  • Customer qualification timelines: while qualification supports the moat, project delays can slow conversion from development to commercial volumes.
  • Environmental, health, and safety (EHS) regulation: compliance and potential product reformulation can raise costs and change competitive dynamics.
  • Capital allocation and execution risk: specialty chemicals require disciplined capacity planning; underutilization or mis-timed expansions can weigh on returns.
  • Competitive intensity in specialties: large diversified peers can subsidize R&D and broaden product offerings into overlapping niches.

📊 Valuation & Market View

Markets generally value specialty chemicals based on a mix of cash generation, earnings quality, and operating leverage, often using EV/EBITDA or adjusted earnings multiples. Key valuation drivers include:

  • Margin durability driven by differentiation and supply reliability.
  • Ability to manage cycles through cost discipline and portfolio mix.
  • Working-capital discipline in environments with volatile input prices.
  • Sustainable reinvestment returns in capacity, technical platforms, and customer programs.

Because specialty chemicals can blend cyclicality with structural differentiation, the market tends to reward businesses that demonstrate consistent operating discipline and credible pathways for product and customer wins.

🔍 Investment Takeaway

Ashland’s investment case rests on application-driven switching costs and technical know-how that embed its specialty products into customer specifications. The moat is reinforced by qualification requirements, formulation complexity, and ongoing technical service, which can limit share loss and support pricing/margin resilience relative to commodity chemical exposures. The principal risks relate to industrial cycle sensitivity, input cost volatility, and EHS/regulatory execution, making disciplined operating performance and portfolio mix the central factors to monitor over time.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for ASH.

seekingalpha.com•2026-06-05

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

zacks.com•2026-05-28

Why Is Ashland (ASH) Up 16.6% Since Last Earnings Report?

Ashland (ASH) reported earnings 30 days ago. What's next for the stock?

zacks.com•2026-05-28

New Strong Sell Stocks for May 28th

BKR, ASH and AB have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2026.

zacks.com•2026-05-22

New Strong Sell Stocks for May 22nd

AOS, EADSY and ASH have been added to the Zacks Rank #5 (Strong Sell) List on May 22, 2026.

prnewswire.com•2026-05-21

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ashland Inc. - ASH

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ashland Inc. ("Ashland" or the "Company") (NYSE: ASH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

globenewswire.com•2026-05-19

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ashland Inc. - ASH

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ashland Inc. (“Ashland” or the “Company”) (NYSE: ASH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

globenewswire.com•2026-05-18

Ashland Board appoints Bertrand Loy as new director

WILMINGTON, Del., May 18, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) is announcing the appointment of Bertrand Loy to its board of directors, effective May 15, 2026.

gurufocus.com•2026-05-15

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ashland Inc. - ASH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ashland Inc. - ASH PR Newswire

prnewswire.com•2026-05-14

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ashland Inc. - ASH

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ashland Inc. ("Ashland" or the "Company") (NYSE: ASH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

globenewswire.com•2026-05-13

ASH Investors Have Opportunity to Join Ashland Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, May 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ashland Inc. (“Ashland” or “the Company”) (NYSE: ASH ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

zacks.com•2026-05-13

New Strong Sell Stocks for May 13th

AB, BKR and ASH have been added to the Zacks Rank #5 (Strong Sell) List on May 13th, 2026.

globenewswire.com•2026-05-12

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ashland Inc. - ASH

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ashland Inc. (“Ashland” or the “Company”) (NYSE: ASH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

prnewswire.com•2026-05-07

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ashland Inc. - ASH

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ashland Inc. ("Ashland" or the "Company") (NYSE: ASH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

globenewswire.com•2026-05-05

Ashland board authorizes quarterly dividend

WILMINGTON, Del., May 05, 2026 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.42 cents per share on the company's common stock which represents a 1.2 percent increase from the previous quarter.

zacks.com•2026-05-04

ASH Q2 Earnings and Sales Miss on Weak Pricing, Intermediates Weakness

ASH posts weaker Q2 results with earnings and sales missing estimates despite gains in Personal Care and steady Life Sciences demand.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"ASH reported 2026-03-31 (most recent quarter) Revenue of $482.0M and Net Income of $16.0M, with EPS of $0.35. Versus the prior quarter (QoQ, 2025-12-31), Revenue rose from $386.0M to $482.0M (+24.9%), and Net Income improved from a loss of $12.0M to a gain of $16.0M (improvement of +$28.0M; turnaround). Versus the same quarter last year (YoY, 2025-03-31), Revenue was essentially flat ($479.0M to $482.0M, +0.6%), while Net Income rose from $31.0M to $16.0M (-48.4%), indicating lower profitability year-over-year. Profitability improved sharply on a QoQ basis: gross margin expanded (30.5% vs 20.7%), and operating margin turned positive (8.1% vs -1.6%). Over the broader 4-quarter window, margins are volatile (notably a severe disruption in Q3 2025 with large losses), but the latest quarter shows clear stabilization. Cash flow quality improved: operating cash flow was $50.0M and free cash flow (FCF) was $33.0M, after a very strong Q1 2026 (FCF $111.0M). The company paid dividends of $19.0M; there were no buybacks in the latest quarter. Balance sheet leverage remains moderate: total assets were $4.50B and equity $1.87B, while net debt decreased to $1.14B from $1.27B in Q1 2026. Total shareholder returns are supported by price momentum: marketPerformance shows a +18.1% 1Y change (below the >20% threshold). With a small dividend yield (~0.7%), total return remains driven primarily by price."

Revenue Growth

Positive

QoQ Revenue grew +24.9% (from $386.0M to $482.0M). YoY Revenue was flat at +0.6% (from $479.0M).

Profitability

Good

Strong QoQ turnaround: Net Income moved from -$12.0M to +$16.0M, and operating margin flipped to +8.1%. YoY profitability weakened: Net Income -48.4% (from $31.0M) despite higher gross margin vs Q1 2026.

Cash Flow Quality

Neutral

FCF was positive at $33.0M and operating cash flow $50.0M, but cash generation is down from Q1 2026 (FCF $111.0M). Dividends ($19.0M) were paid; payout ratios in the latest quarter indicate limited room for stress.

Leverage & Balance Sheet

Neutral

Assets were $4.50B; equity was stable near $1.87B. Net debt improved to $1.14B from $1.27B QoQ, but leverage remains meaningful with total debt ~$1.48B.

Shareholder Returns

Neutral

Price momentum is positive (+18.1% 1Y) but not above the >20% strong-momentum threshold. Dividend yield is low (~0.7%); buybacks were not evident in the latest quarter.

Analyst Sentiment & Valuation

Positive

Consensus target ($68.43) is above the current price ($58.52), implying upside (~17%). High multiple risk remains given profitability volatility across recent quarters.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Ashland’s Q2 2026 results show resilient end-market demand but meaningful earnings drag from internal execution and temporary plant disruptions. Consolidated sales were $482M (+1% YoY) with FX adding ~3%, while pricing declined modestly and volumes were broadly stable. The company’s adjusted EBITDA fell 9% to $98M; margin dropped ~220 bps to ~20%, driven largely by Calvert City restart delays and weather disruptions. The margin bridge is critical: once discrete items are excluded, management highlights cost discipline and FX benefits. However, Specialty Additives and Intermediates faced additional execution friction—Hopewell HEC scale-up productivity/yield/cost ramp slower than planned, plus a Middle East energy customer bad-debt reserve and weather impacts—pushing Specialty Additives margin to 11.9%. The company cut FY26 manufacturing optimization benefit by ~$10M–$12M due to Hopewell timing, but maintained sustainable annual cost-savings targets ($50M–$55M, up to ~$60M). Guidance expects pricing upside, while demand recovery uncertainty (coatings, EV-related intermediates, Middle East) keeps sentiment mixed.

AI IconGrowth Catalysts

  • Life Sciences: Injectables sustained growth with a record Q2 and positive lead indicators (pipeline, new uptake, new orders); tablet coatings and differentiated cellulose excipients supporting steady pharma demand
  • Life Sciences: Expanding adoption of low-nitride oral solid dosage excipients plus high-purity injectable and bioprocessing products; positioned for multiple 2H launches (oral solid dose injectables and Crop Care)
  • Personal Care: Biofunctional actives delivering robust double-digit YoY growth; microbial protection gaining share post globalized investments
  • Innovation platform momentum: Innovate exceeded full-year target after 2 quarters and delivered ~ $10 million incremental sales in Q2; Globalize/Innovate combined confidence in a $35 million FY26 revenue commitment
  • Innovation launches: Essernonite (2026 flagship ingredient) recognized at In-Cosmetics Global; Care Ingredients VR-based conditioning polymer gaining customer adoption

Business Development

  • Personal Care: Customer expansions across Europe and North America supporting biofunctional actives growth (named product/customer details not provided)
  • Life Sciences: Echelon differentiation in regulated, high-value markets; new product success in low nitride oral solid dose and high-purity injectable/bioprocessing applications (customer names not provided)
  • Innovation: GLP-1-related applications mentioned as emerging contribution within Innovate (no partner named)

AI IconFinancial Highlights

  • Consolidated sales: $482 million, +1% YoY; pricing declined modestly YoY with volume relatively stable; FX tailwind ~ $16 million (+3% to reported sales)
  • Adjusted EBITDA: $98 million, -9% YoY; margin ~20%, down 220 bps YoY, primarily from temporary operational disruptions (Calvert City start-up delay + weather-related disruptions); underlying performance excluding discrete items reflects softer pricing offset by disciplined costs and FX
  • Adjusted EPS (ex-intangibles): $0.91, -8% YoY
  • Cash flow: Operating cash flow $50 million vs $9 million prior year; free cash flow $29 million (conversion driven by working capital and reduced capex)
  • Life Sciences: Sales $172 million flat YoY; Adjusted EBITDA margin 29%, down YoY with impacts from ~ $5 million weather disruption and Calvert City start-up delays
  • Intermediates: Sales $35 million, -5% YoY; Adjusted EBITDA $5 million vs $2 million prior year quarter (cost management + favorable manufacturing input actions offset Calvert City impacts and BDO trough pressure)
  • Personal Care: Sales $150 million, +3% YoY (+4% comparable); Adjusted EBITDA margin ~29% (slight decline from operational/weather outages offset by volume/mix); FX to sales ~$5 million
  • Specialty Additives: Sales $134 million flat YoY; Adjusted EBITDA $16 million vs $26 million prior year; margin 11.9% (down YoY) from softer pricing, higher manufacturing-related costs including ~$2 million weather disruptions, a discrete bad debt reserve for a Middle East energy customer, and Hopewell scale-up productivity/yield issues

AI IconCapital Funding

  • Liquidity: total available liquidity ~ $939 million; net debt just over $1 billion
  • Net leverage: ~2.7x
  • No buyback amount or incremental debt/cash runway figures provided in transcript

AI IconStrategy & Ops

  • Calvert City: Repairs complete; facility back online; Q2 EBITDA margin pressure tied to Calvert City start-up delay (discrete $ impacts referenced) and weather disruptions
  • Hopewell (HEC scale-up): productivity/yield/cost performance ramp slower than planned; targeted actions include tightening operating discipline, increased leadership focus, and technical workstreams; sequential improvement noted but financial benefits delayed
  • Manufacturing optimization benefit: reduced FY26 by ~$10 million to $12 million due to Hopewell timing delays (opportunity intact; delayed realization)
  • Cost savings outlook: sustainable annual manufacturing optimization cost savings expected $50 million to $55 million; opportunity up to ~$60 million as China volumes recover
  • Globalize/Innovate: Globalize incremental contribution ~ $8 million to $11 million FYTD; Innovate delivered ~$10 million incremental sales in the quarter and exceeded full-year target after 2 quarters
  • Innovation platforms: transformed vegetable oil progressing toward early commercialization; super wedding agents (PFAS-free, silicon-free) expanding across multiple end markets; bioresorbable polymers gaining momentum for long-acting injectables and medical devices

AI IconMarket Outlook

  • FY26 updated guidance (range): Sales $1.835B to $1.87B; Adjusted EBITDA $385M to $400M
  • FY26 adjusted EPS growth: mid-single to high-single digit growth (directional, no point estimate)
  • FY26 free cash flow conversion: ~50% of adjusted EBITDA
  • Guidance assumptions emphasized: Life Sciences and Personal Care resilient; Specialty Additives/Intermediates at trough levels with coatings recovery expected gradual/regionally uneven; raw material/logistics costs trending higher; pricing actions expected to offset
  • Q3 demand commentary: management cited encouraging Q3 demand trends; analysts asked about price realization and operational steps to reach top-end EBITDA

AI IconRisks & Headwinds

  • Adjusted EBITDA margin down 220 bps YoY from temporary operational disruptions (Calvert City start-up delay + weather disruptions)
  • Hopewell HEC scale-up productivity/yield/cost ramp below plan; operational execution risk delaying near-term financial benefits
  • Specialty Additives: bad debt reserve for a Middle East energy customer (discrete) and higher manufacturing-related costs; profitability impacted by Hopewell scale-up challenges
  • Macro/geopolitics: Middle East conflict tied to softer energy-related demand; MENA represents ~5% of total sales and has no manufacturing footprint, but sales/demand impacts still referenced
  • EV-driven demand delays (Intermediates) and delays in EV projects referenced as a contributor to guidance trimming
  • North America/Europe coatings customers cited as more prudent, creating uncertainty on demand recovery timing

Q&A: Analyst Interest

  • Topic: Pricing and cost catch-up vs lowered guidance—Management detailed that each business is executing announced price increases/surcharges region-by-region and product-by-product, moving like 2022; benefits start flowing “this month” and into coming months. Guidance trim was driven by Middle East demand declines, credit issues expected to recover, and EV project delays rather than lack of pricing execution.
  • Topic: What’s needed for top-end FY26 EBITDA range—Management said pricing is an upside, while conservatism comes from uncertainty mostly in Specialty Additives and Intermediates. They framed low-end as mostly pricing with flattish volumes; higher-end implies ~6%–7% sales growth balanced volume and price, plus continued Globalize/Innovate delivery and execution outside those platforms.
  • Topic: Specialty Additives one-time events and Q3 outlook—Management began to quantify, stating the larger year-to-date impact was Calvert City (affecting multiple business lines), but the transcript truncates before a full Specialty Additives discrete total or explicit Q3 operating-income growth expectation.

Sentiment: MIXED

Note: This summary was synthesized by AI from the ASH Q2 2026 (ended 2026-04-29) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for ASH.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (ASH)

© 2026 Stock Market Info — Ashland Inc. (ASH) Financial Profile